Indaptus Therapeutics Debt
INDP Stock | USD 1.65 0.01 0.60% |
Indaptus Therapeutics holds a debt-to-equity ratio of 0.004. At this time, Indaptus Therapeutics' Short and Long Term Debt Total is relatively stable compared to the past year. As of 08/31/2024, Short Term Debt is likely to grow to about 147.1 K, while Interest Debt Per Share is likely to drop 0.02. . Indaptus Therapeutics' financial risk is the risk to Indaptus Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Indaptus Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Indaptus Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Indaptus Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Indaptus Therapeutics' stakeholders.
For most companies, including Indaptus Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Indaptus Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Indaptus Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 2.7243 | Book Value 0.721 | Return On Assets (0.71) | Return On Equity (1.27) |
Indaptus |
Indaptus Therapeutics Bond Ratings
Indaptus Therapeutics financial ratings play a critical role in determining how much Indaptus Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Indaptus Therapeutics' borrowing costs.Piotroski F Score | 4 | Poor | View |
Beneish M Score | (5.31) | Unlikely Manipulator | View |
Indaptus Therapeutics Debt to Cash Allocation
Indaptus Therapeutics currently holds 175.05 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Indaptus Therapeutics has a current ratio of 9.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Indaptus Therapeutics' use of debt, we should always consider it together with its cash and equity.Indaptus Therapeutics Total Assets Over Time
Indaptus Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Indaptus Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Indaptus Therapeutics Debt Ratio | 1.22 |
Indaptus Therapeutics Corporate Bonds Issued
Indaptus Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Indaptus Therapeutics Use of Financial Leverage
Indaptus Therapeutics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Indaptus Therapeutics' current equity. If creditors own a majority of Indaptus Therapeutics' assets, the company is considered highly leveraged. Understanding the composition and structure of Indaptus Therapeutics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 175.1 K | 310 K | |
Net Debt | -13.2 M | -13.8 M | |
Short Term Debt | 101.7 K | 147.1 K | |
Net Debt To EBITDA | 0.81 | 0.76 | |
Debt To Equity | 0.01 | 0.02 | |
Interest Debt Per Share | 0.02 | 0.02 | |
Debt To Assets | 0.01 | 0.01 | |
Total Debt To Capitalization | 0.01 | 0.02 | |
Debt Equity Ratio | 0.01 | 0.02 | |
Debt Ratio | 0.01 | 0.01 | |
Cash Flow To Debt Ratio | (76.58) | (80.41) |
Pair Trading with Indaptus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Indaptus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Indaptus Stock
Moving against Indaptus Stock
0.85 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.85 | GILD | Gilead Sciences | PairCorr |
0.82 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.39 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
0.38 | TIL | Instil Bio Upward Rally | PairCorr |
The ability to find closely correlated positions to Indaptus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Indaptus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Indaptus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Indaptus Therapeutics to buy it.
The correlation of Indaptus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Indaptus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Indaptus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Indaptus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.